Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies.

Foster, John G; Blunt, Matthew D; Carter, Edward; Ward, Stephen G

Foster, John G; Blunt, Matthew D; Carter, Edward; Ward, Stephen G.

Affiliation

Foster JG; Inflammatory Cell Biology Laboratory, Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath, UK. s.g.ward@bath.ac.uk

Pharmacol Rev ; 64(4): 1027-54, 2012 Oct.

Article in En | MEDLINE | ID: mdl-23023033

Subject(s)

Autoimmune Diseases/enzymology; Hematologic Neoplasms/enzymology; Phosphatidylinositol 3-Kinases/immunology; Animals; Autoimmune Diseases/drug therapy; Autoimmune Diseases/immunology; Enzyme Inhibitors/pharmacology; Hematologic Neoplasms/drug therapy; Hematologic Neoplasms/immunology; Humans; Immune System/enzymology; Inflammation/drug therapy; Inflammation/enzymology; Inflammation/immunology; Phosphatidylinositol 3-Kinases/chemistry; Phosphoinositide-3 Kinase Inhibitors; Protein Structure, Tertiary; Signal Transduction

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Autoimmune Diseases / Hematologic Neoplasms / Phosphatidylinositol 3-Kinases Limits: Animals / Humans Language: En Year: 2012 Type: Article

Fulltext

XML

PubMed Links

Search on Google